Show Description +
This animation shows two ways to perform MicroPulse Transscleral Laser Therapy utilizing the revised MicroPulse P3 Probe. One option is to perform the procedure in quadrants (2500 mw, 5 sweeps, 10 seconds per sweep) and the other approach is to perform it in hemispheres (2500 mw, 5 sweeps, 20 seconds per sweep). MicroPulse TLT is is a non-incisional procedure that substantially reduces IOP for a broad range of glaucoma patients. The revised MicroPulse P3 Device has a smooth, ergonomic interface to allow clinicians to keep consistent contact with the probe at the limbus. The device offers a repeatable treatment option that can be introduced before, in combination with, or after other glaucoma treatment options - making it a very versatile tool.
Posted: 8/29/2023
This animation shows two ways to perform MicroPulse Transscleral Laser Therapy utilizing the revised MicroPulse P3 Probe. One option is to perform the procedure in quadrants (2500 mw, 5 sweeps, 10 seconds per sweep) and the other approach is to perform it in hemispheres (2500 mw, 5 sweeps, 20 seconds per sweep). MicroPulse TLT is is a non-incisional procedure that substantially reduces IOP for a broad range of glaucoma patients. The revised MicroPulse P3 Device has a smooth, ergonomic interface to allow clinicians to keep consistent contact with the probe at the limbus. The device offers a repeatable treatment option that can be introduced before, in combination with, or after other glaucoma treatment options - making it a very versatile tool.
Posted: 8/29/2023
Treat and Extend with PASCAL Laser
DIAMONDS: A Randomized Controlled Trial Designed with Patients in Mind
The Clinical and Economic Argument for MicroPulse® Laser in a Retinal Practice
Comprehensive Ophthalmologists Discuss Practice Benefits of Transscleral Laser Therapy (TLT) with MicroPulse® Technology for a Broad Range of Glaucoma Patients
MicroPulse® Transscleral Laser Therapy for the Treatment of Glaucoma: Guidelines from an International Delphi Panel
About Iridex
Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems for the ophthalmology market. The Company’s proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME), and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors.
Follow Iridex